ARYx Therapeutics (ARYx Therapeutics) Capex-to-Revenue : 0.00 (As of Sep. 2010)

View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

ARYx Therapeutics's Capital Expenditure for the three months ended in Sep. 2010 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2010 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

ARYx Therapeutics Capex-to-Revenue Historical Data

The historical data trend for ARYx Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYx Therapeutics Capex-to-Revenue Chart

ARYx Therapeutics Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Capex-to-Revenue

Get a 7-Day Free Trial

0.20

0.12

0.03

ARYx Therapeutics Quarterly Data
	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10
Capex-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ARYx Therapeutics's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, ARYx Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARYx Therapeutics's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ARYx Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where ARYx Therapeutics's Capex-to-Revenue falls into.

ARYx Therapeutics Capex-to-Revenue Calculation

ARYx Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2009 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.141)	/	0
	=	N/A

ARYx Therapeutics's Capex-to-Revenue for the quarter that ended in Sep. 2010 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

ARYx Therapeutics (OTCPK:ARYX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

ARYx Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ARYx Therapeutics (ARYx Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

6300 Dumbarton Circle, Fremont, CA, USA, 94555

Website

http://www.aryx.com

ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.

Executives

Newhall Charles W Iii	10 percent owner	1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri	10 percent owner
New Enterprise Associates 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry	10 percent owner
Patrick J Kerins	10 percent owner
Forest Baskett	10 percent owner
Growth Equity Opportunities Fund, Llc	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell	10 percent owner
Nicholas Galakatos	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines